Envista (NYSE:NVST) Hits New 1-Year High Following Analyst Upgrade

Shares of Envista Holdings Corporation (NYSE:NVST) reached a new 52-week high during mid-day trading on Thursday after Barclays raised their price target on the stock from $24.00 to $34.00. Barclays currently has an overweight rating on the stock. Envista traded as high as $30.42 and last traded at $30.1890, with a volume of 3500017 shares trading hands. The stock had previously closed at $30.17.

Several other analysts also recently weighed in on the company. Wall Street Zen upgraded Envista from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 26th. Weiss Ratings reissued a “sell (d)” rating on shares of Envista in a research report on Monday, December 29th. JPMorgan Chase & Co. boosted their target price on shares of Envista from $22.00 to $26.00 and gave the stock a “neutral” rating in a research report on Friday, February 6th. Leerink Partners set a $35.00 price target on shares of Envista and gave the company an “outperform” rating in a report on Friday, February 6th. Finally, Wells Fargo & Company raised their price target on shares of Envista from $21.00 to $26.00 and gave the stock an “equal weight” rating in a research report on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Envista presently has an average rating of “Moderate Buy” and a consensus target price of $27.43.

Insider Transactions at Envista

In other news, SVP Mischa Reis sold 9,675 shares of the stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $30.00, for a total value of $290,250.00. Following the completion of the transaction, the senior vice president directly owned 32,382 shares of the company’s stock, valued at approximately $971,460. This represents a 23.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.66% of the stock is owned by company insiders.

Envista News Roundup

Here are the key news stories impacting Envista this week:

• Positive Sentiment: Q4 EPS and revenue beat drove early upside — Zacks reports NVST jumped after the quarter as EPS and revenue topped expectations and segments showed double-digit growth despite margin pressure. Read More.
• Positive Sentiment: Barclays raised its price target to $34 and moved the stock to “overweight,” giving Wall Street momentum and a stronger institutional narrative behind the rally. Read More.
• Positive Sentiment: Broker recognition: NVST was added to Zacks’ top growth list (Zacks Rank #1), which can attract momentum and growth-focused flows. Read More.
• Neutral Sentiment: Mizuho nudged its target higher to $27 but kept a neutral rating — a modest endorsement that is less bullish than some peers and may temper further upside. Read More.
• Negative Sentiment: Underlying profitability concerns: a Quiver summary shows Q4 revenue grew modestly, but Envista reported a large operating loss (~$337M) and net loss (~$372M), which weighs on the sustainability of the EPS beat and investor confidence. Cash remains healthy, but the losses are a material negative. Read More.
• Negative Sentiment: Insider and institutional selling: SVP Mischa Reis disclosed a sale (~9,675 shares) and major funds have trimmed stakes recently (e.g., Morgan Stanley, BlackRock, Point72), which can pressure the stock and prompt profit-taking. Read More. • Read More.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada grew its holdings in shares of Envista by 26.6% in the 1st quarter. Royal Bank of Canada now owns 23,240 shares of the company’s stock worth $401,000 after purchasing an additional 4,885 shares during the last quarter. Millennium Management LLC boosted its position in Envista by 218.6% in the first quarter. Millennium Management LLC now owns 383,966 shares of the company’s stock valued at $6,627,000 after buying an additional 263,442 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Envista by 39.3% during the first quarter. Goldman Sachs Group Inc. now owns 629,140 shares of the company’s stock worth $10,859,000 after buying an additional 177,630 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Envista by 15.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 568,982 shares of the company’s stock worth $9,821,000 after buying an additional 76,246 shares in the last quarter. Finally, KLP Kapitalforvaltning AS increased its holdings in shares of Envista by 11.3% during the second quarter. KLP Kapitalforvaltning AS now owns 36,400 shares of the company’s stock worth $711,000 after buying an additional 3,700 shares in the last quarter.

Envista Stock Down 5.1%

The company has a market cap of $4.72 billion, a P/E ratio of 102.61, a PEG ratio of 2.07 and a beta of 1.01. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.38 and a quick ratio of 2.04. The business’s 50 day moving average price is $23.54 and its 200-day moving average price is $21.48.

Envista (NYSE:NVST) last released its quarterly earnings results on Thursday, February 5th. The company reported $0.38 earnings per share for the quarter, beating analysts’ consensus estimates of $0.32 by $0.06. Envista had a return on equity of 6.54% and a net margin of 1.73%.During the same quarter in the previous year, the business posted $0.24 earnings per share. Envista’s revenue was up 15.0% on a year-over-year basis. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. On average, analysts anticipate that Envista Holdings Corporation will post 1 earnings per share for the current fiscal year.

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.